- FDA authorizes StemCells to conduct trial of product candidate in patients with age-related macular degeneration
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA removes clinical hold on trial of Idenix's investigational HCV therapy
- Discovery Labs' aerosol drug delivery system approved
- Merck's Janumet XR approved for type 2 diabetes
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Drug company to suspend Celebrex advertising
Sunday, January 02 2005 | Comments
What's This?
Pfizer Inc. is suspending its direct-to-consumer advertising of Celebrex (celecoxib) in light of recent news that the painkiller has been linked in one study to an increased risk of cardiovascular events and after discussions with the Food and Drug Administration.
The stop in advertising covers radio, newspaper and magazine promotions, although the company plans to continue marketing Celebrex to physicians.
The FDA asked Pfizer to inform physicians of the study results that showed the increased risk of heart problems in order to ensure that the doctors are aware of the new findings. It also asked Pfizer to include the FDA's recommendations about the drug's use.
Specifically, while the agency recognized the preliminary nature of the new information about the potential cardiovascular problems associated with higher doses of Celebrex, it still recommended that physicians evaluate alternative therapies for their patients currently using Celebrex.
"At this time, if physicians determine that continued use is appropriate for individual patients, FDA advises the use of the lowest effective dose of Celebrex," the regulatory body said in a statement.
The FDA is in the process of obtaining all available data from other ongoing Celebrex trials and will determine the appropriate regulatory action as soon as possible.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- Anterior labroligamentous periosteal avulsion lesions may be associated with higher rate of recurrent dislocations than Bankart lesions following arthroscopic capsulolabral repair
- Combined use of ESR, CRP effective screening tool for ruling out periprosthetic infection after TKA, researchers find
- Laminar airflow ventilation during orthopedic, abdominal procedures does not prevent surgical site infections, study suggests
- Metatarsophalangeal joint arthroscopy may reduce metatarsophalangeal joint pain in patients with hallux valgus
- Hypoxemia following total joint arthroplasty may predict medical complications, researchers suggest
- Prophylactic antibiotics effective immediately following knee arthroplasty
- Lifting training does not prevent back pain or disability
- Removable splints may be as good as casts for minor wrist fractures in children
- Diabetics more likely to have carpal tunnel surgery
- Anterior labroligamentous periosteal avulsion lesions may be associated with higher rate of recurrent dislocations than Bankart lesions following arthroscopic capsulolabral repair
